A257 Mid-term experience with the artisse for the treatment of MCA aneurysms: a single-center study

<h3>Introduction</h3> The treatment of wide-neck middle cerebral artery (MCA) aneurysms poses a unique challenge in endovascular neurosurgery. The Artisse intrasaccular flow disruptor (Medtronic) is a novel device designed to facilitate aneurysm occlusion while reducing reliance on adjunctive devices and prolonged antiplatelet therapy. <h3>Aim of study</h3> To evaluate the mid-term safety, feasibility, and angiographic outcomes of the Artisse device in treating wide-neck MCA aneurysms. <h3>Method</h3> Seven patients (six women, one man; mean age 60) with MCA aneurysms were treated with the Artisse device between August and September 2024. Five aneurysms were at the M1/M2 bifurcation, and two on the M1 segment. All patients received dual antiplatelet therapy. Artisse deployment was performed using a Rebar 18 microcatheter, with post-procedural DSA follow-up at 3 or 4 months. Outcomes were assessed via the Raymond-Roy occlusion classification. <h3>Results</h3> Device deployment was technically successful in all seven cases. Complete occlusion (Raymond-Roy Class I) was achieved in six cases; one had near-complete occlusion (Class II). No major procedural complications occurred. One transient M2 occlusion was resolved with stent deployment, followed by a transient ischemic attack, without imaging evidence of infarction or vessel compromise. <h3>Conclusion</h3> The Artisse device appears to be a safe and effective option for treating wide-neck MCA aneurysms. Mid-term follow-up demonstrated high occlusion rates and favorable procedural outcomes. Larger studies with extended follow-up are warranted to confirm these findings. <h3>Conflict of Interest</h3> No